NASDAQ: MEIP - MEI Pharma, Inc.

Rentabilité sur six mois: -12.86%
Secteur: Healthcare

Calendrier des promotions MEI Pharma, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies.

plus de détails
It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

EBITDA -0.0738
EV/EBITDA -2.32
IPO date 2003-12-19
ISIN US55279B2025
Industry Biotechnology
P/BV 3.78
P/E 1.04
P/S 36.82
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.0049
Див.доход ао 0
Дивиденд ао 1.75
Сайт https://www.meipharma.com
Цена ао 3.86
Число акций ао 0.00666 млрд
Changement de prix par jour: +2.52% (2.38)
Changement de prix par semaine: -2.4% (2.5)
Changement de prix par mois: -12.86% (2.8)
Changement de prix sur 3 mois: -15.86% (2.9)
Changement de prix sur six mois: -12.86% (2.8)
Changement de prix par an: -57.93% (5.8)
Evolution du prix sur 3 ans: +0.8264% (2.42)
Evolution du prix sur 5 ans: +31.89% (1.85)
Evolution des prix sur 10 ans: 0% (2.44)
Evolution des prix depuis le début de l'année: +3.39% (2.36)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0.2837 10
P/BV 0.561 10
P/E 1.04 10
EV/EBITDA 0.5617 10
Total: 10

Efficacité

Nom Signification Grade
ROA, % 21.92 7
ROE, % 61.68 10
Total: 7.5

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0.5 5
Total: 2.35

Devoir

Nom Signification Grade
Debt/EBITDA 0.4825 10
Total: 9.6

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 125.94 10
Rentabilité Ebitda, % -1748.75 0
Rentabilité EPS, % -126.42 0
Total: 2
Plus de détails

Dividende, % Dividende Sur la base des résultats de la période Acheter avant Date de clôture du registre Paiement avant
45.34% 1.75 III кв. 2023 14.11.2023 16.11.2023 01.12.2023
Plus de détails

Établissements Volume Partager, %
Anson Funds Management LP 1093188 16.41
Cable Car Capital LLC 611440 9.18
Vanguard Group Inc 389807 5.85
Tang Capital Management, LLC 326084 4.89
Acadian Asset Management. LLC 225391 3.38
Renaissance Technologies, LLC 150892 2.26
Blackrock Inc. 83318 1.25
Carlson Capital. L.P. 74000 1.11
Geode Capital Management, LLC 51616 0.77
Macquarie Group Limited 29999 0.45



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Justin J. File Acting CEO, CFO & Corporate Secretary N/A 1970 (55 années)
Ms. Yomara Gomez-Naiden Senior Vice President of Operations & Quality N/A
Ms. Nicole Chyoko Iida Vice President of Legal Affairs N/A
Ms. Anne Frese Chief People Officer N/A
Dr. Robert D. Mass Strategic Advisor 201.68k 1954 (71 année)
Mr. David A. Walsey J.D., L.L.M. Senior Vice President of Corporate Affairs N/A

Adresse: United States, San Diego. CA, 11455 El Camino Real - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.meipharma.com